Health Care

Eli Lilly and Co (NYSE:LLY) Stock Analyst Ratings Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 02/16/2024 21.39% Morgan Stanley $805 → $950 Maintains Overweight 02/14/2024 4.14% Cantor Fitzgerald → $815 Reiterates Overweight → Overweight 02/07/2024 8.61% Truist Securities $650 → $850 Maintains Buy 02/07/2024 2.86% Morgan Stanley $763 → $805 Maintains Overweight 02/07/2024 3.5% Barclays $680 → $810 Maintains Overweight 02/07/2024 5.42% Wells Fargo $700 → $825 Maintains Overweight 02/07/2024 10.53% BMO Capital $710 → $865 Maintains Outperform 02/06/2024 5.42% Wells Fargo $700 → $825 Maintains Overweight 02/06/2024 4.14% Cantor Fitzgerald $630 → $815 Maintains Overweight 02/05/2024 -19.5% Cantor Fitzgerald → $630 Reiterates Overweight → Overweight 02/01/2024 -19.5% Cantor Fitzgerald → $630 Reiterates Overweight → Overweight 01/24/2024 -10.56% Wells Fargo $650 → $700 Maintains Overweight 01/23/2024 -19.5% Cantor Fitzgerald → $630 Reiterates Overweight → Overweight 01/23/2024 -13.11% Barclays $630 → $680 Maintains Overweight 12/21/2023 […]

Eli Lilly and Co (NYSE:LLY) Stock Analyst Ratings Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 02/14/2024 8.29% Cantor Fitzgerald → $815 Reiterates Overweight → Overweight 02/07/2024 12.94% Truist Securities $650 → $850 Maintains Buy 02/07/2024 6.96% Morgan Stanley $763 → $805 Maintains Overweight 02/07/2024 7.62% Barclays $680 → $810 Maintains Overweight 02/07/2024 9.62% Wells Fargo $700 → $825 Maintains Overweight 02/07/2024 14.93% BMO Capital $710 → $865 Maintains Outperform 02/06/2024 9.62% Wells Fargo $700 → $825 Maintains Overweight 02/06/2024 8.29% Cantor Fitzgerald $630 → $815 Maintains Overweight 02/05/2024 -16.29% Cantor Fitzgerald → $630 Reiterates Overweight → Overweight 02/01/2024 -16.29% Cantor Fitzgerald → $630 Reiterates Overweight → Overweight 01/24/2024 -6.99% Wells Fargo $650 → $700 Maintains Overweight 01/23/2024 -16.29% Cantor Fitzgerald → $630 Reiterates Overweight → Overweight 01/23/2024 -9.65% Barclays $630 → $680 Maintains Overweight 12/21/2023 -18.95% Daiwa Capital → $610 Downgrades Buy → Outperform

Cantor Fitzgerald analyst Louise Chen reiterates Eli Lilly (NYSE:LLY) with a Overweight and maintains $815 price target.

CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: Following LLY’s solid Q4 earnings release this morning, we lift our target price by $86 to $788, 50.9x our projected 2025 EPS, above LLY’s historical forward P/E average, justified by LLY’s strong revenue and earnings growth potential. We raise our 2024 EPS estimate by $0.23 to $12.40, which points to 96% Y/Y growth. We initiate our 2025 view at $15.47. LLY posted Q4 EPS of $2.49 vs. $2.09, a noteworthy +19% Y/Y, $0.12 above the consensus. Q4 revenues of $9.4B, up 28% Y/Y, came in $152M above our estimate and $383M above consensus, driven by higher-than-expected sales for the obesity treatments Mounjaro ($2.2B) and the newly launched Zepbound ($176M). We expect 2024 to be another year of strong growth and pencil in a 19% Y/Y top-line sales

Eli Lilly and Co (NYSE:LLY) Stock Analyst Ratings Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 02/06/2024 16.42% Cantor Fitzgerald $630 → $815 Maintains Overweight 02/05/2024 -10.01% Cantor Fitzgerald → $630 Reiterates Overweight → Overweight 02/01/2024 -10.01% Cantor Fitzgerald → $630 Reiterates Overweight → Overweight 01/24/2024 -0.01% Wells Fargo $650 → $700 Maintains Overweight 01/23/2024 -10.01% Cantor Fitzgerald → $630 Reiterates Overweight → Overweight 01/23/2024 -2.86% Barclays $630 → $680 Maintains Overweight 12/21/2023 -12.86% Daiwa Capital → $610 Downgrades Buy → Outperform 11/29/2023 -7.15% Truist Securities → $650 Reiterates Buy → Buy 11/20/2023 -10.01% Cantor Fitzgerald → $630 Reiterates Overweight → Overweight 11/17/2023 -10.01% Cantor Fitzgerald → $630 Reiterates Overweight → Overweight 11/15/2023 -10.01% Cantor Fitzgerald → $630 Reiterates Overweight → Overweight 11/09/2023 -23.58% Deutsche Bank → $535 Initiates Coverage On → Hold 11/08/2023 — JP Morgan Reiterates → Overweight 11/03/2023 3.13% Morgan Stanley $673

The following is a summary of the Eli Lilly and Co (LLY) Q4 2023 Earnings Conference Call Transcript: Financial Performance: Eli Lilly’s revenue grew 20% for the full year and 28% for Q4 in 2023; new products contributed over $2 billion growth. Distributed over $1 billion in dividends in Q4, announced a 15% dividend increase for the sixth consecutive year. Q4 revenue increased by 28% compared to Q4 2022 due to acceleration in revenue growth powered by Mounjaro, Verzenio, Jardiance, and Zepbound. Gross margin as a percentage of revenue grew to 82.3% on account of higher realized prices. Operating income rose by 29%, driven by higher revenue from new launches. Earnings per share for Q4 were $2.49, a 19% increase from Q4 2022. U.S. revenue was up by 39% in Q4 owing to the strong performance of Mounjaro, Verzenio, and Zepbound. Q4 revenue for Europe was up by 11%, 15%

Eli Lilly Sees FY Adj EPS $12.20-Adj EPS $12.70.

Eli Lilly (NYSE:LLY) reported quarterly earnings of $2.49 per share which beat the analyst consensus estimate of $2.19 by 13.7 percent. This is a 19.14 percent increase over earnings of $2.09 per share from the same period last year. The company reported quarterly sales of $9.35 billion which beat the analyst consensus estimate of $8.93 billion by 4.74 percent. This is a 28.09 percent increase over sales of $7.30 billion the same period last year.